I asked Doug Kell about this specifically, and he said that the experimentalists were blinded to case/control status.
Hi, Chris--thanks for clarifying that! Do you have any more insights into some of the other concerns mentioned in this thread?
I asked Doug Kell about this specifically, and he said that the experimentalists were blinded to case/control status.
Hi Jonathan. I asked Doug Kell about this specifically, and he said that the experimentalists were blinded to case/control status.
I asked Douglas Kell about this striking elevated level of % Area Amyloid for type 2 diabetes (relative to controls). He agreed that they had seen this effect for type 2 diabetes and that this means that a metric of “preformed amyloid microclots” cannot - taken in isolation - be diagnostic of ME/CFS or Long Covid. However, he does think that other metrics derived from the microscopy images could be diagnostic - no evidence as yet.The results of that figure look like a major difference but the authors reported even larger differences for diabetes type 2 and covid-19 in a 2020 paper:
The 2022 results on 25 ME patients and 15 controls:
View attachment 17404
2020 results of 10 healthy controls, 10 diabetes patients and 20 covid-19 patients
View attachment 17405
Reported here:
https://cardiab.biomedcentral.com/track/pdf/10.1186/s12933-020-01165-7.pdf
Thanks for looking into this, much appreciated.I asked Douglas Kell about this striking elevated level of % Area Amyloid for type 2 diabetes (relative to controls).
If there are any clots in the 5-100 micron range ('micro clots') they should be spun down with the platelets.
Wouldn't this depend on their density and form?
Loose uncondensed fibrin clot may have almost the same density as plasma but these particles look like fairly solid protein lumps
The conclusion from all this for me is that these studies do not show the presence of microclots in patients. They show the formation of microclots in plasma from patients under lab conditions. That may indicate something odd about the patient's clotting but if was as simple as that why do these clots not extend? It seems maybe the process is more related to amyloid accretion than fibrin clotting. What implications that might have in living patients is unclear to me.
Are these small (roughly platelet sized) very bright areas actually physically dense or is that a product of the density of binding sites for ThT, the intensity of fluorescence, and the sensor and image processing?
I spoke to an academic haematologist with expertise in clotting today. They had not heard of any of the Pretorius work or the methods being used. The more I look at the pictures the less they mean to me.
Will he try to check her work or the methods being used? Did he say what he thinks about?